Biocept (NASDAQ:BIOC) is scheduled to be releasing its earnings data after the market closes on Tuesday, August 14th. Analysts expect Biocept to post earnings of ($3.30) per share for the quarter.
Biocept (NASDAQ:BIOC) last announced its earnings results on Tuesday, May 15th. The medical research company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Biocept had a negative net margin of 561.47% and a negative return on equity of 445.14%. The company had revenue of $0.81 million for the quarter, compared to analysts’ expectations of $1.21 million. On average, analysts expect Biocept to post $-9 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Shares of Biocept opened at $4.02 on Monday, according to Marketbeat. Biocept has a 12 month low of $3.50 and a 12 month high of $44.10. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.31 and a current ratio of 2.41.
Biocept Company Profile
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
Featured Article: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.